La hipertension arterial sistolica aislada es un padecimiento frecuente en ancianos, y constituye el principal factor de riesgo cardiovascular para enfermedad vascular cerebral (EVC) e infarto agudo del miocardio (IAM) dentro de este grupo de pacientes. Las actuales guias de tratamiento favorecen el uso de terapia farmacologica con diureticos de tipo tiazidico, grupo al que pertenece la indapamida, como farmacos de primera linea. Como objetivo primario, se examino la eficacia de indapamida de liberacion prolongada (SR) de 1.5 mg para disminuir la presion sistolica. Material y metodos: Se trato de un estudio experimental, abierto, longitudinal, descriptivo, prospectivo, no comparativo, no controlado, no aleatorizado y de investigacion clinica. 35 pacientes mayores de 60 anos diagnosticados con hipertension arterial sistolica aislada fueron incluidos en el estudio, se mantuvo un seguimiento de los pacientes para medir presion arterial y os siguientes parametros metabolicos: glucosa serica, microalbuminuria, colesterol total y trigliceridos. Resultados: Indapamida SR mostro ser eficaz al disminuir las cifras de tension arterial sistolica en mas de 10 mmHg o mas respecto a la basal. El valor promedio basal de la presion arterial sistolica fue 179.58 ± 13.98 mmHg y despues de 12 meses de tratamiento con indapamida SR se logro alcanzar una cifra promedio de 133.80 ± 10.43 mmHg, descenso que fue estadisticamente significativo (p<0.05). Indapamida SR tambien logro disminuciones en las cifras de presion diastolica con un promedio inicial de 81.66 ± 8.68 mmHg y despues de 12 meses de tratamiento descendio a 75.47 ± 8.02 mmHg (p<0.05). Isolated systolic hypertension is a frequent condition among the elderly and constitutes the main risk factor for cerebrovascular disease (CVD) and acute myocardial infarction (AMI) in patients within this age group.Present treatment guidelines favor the use of pharmacological therapy with thiazide diuretics, one of these being indapamide, as first-line medication. The main objective was to examine the efficiency of indapamide sustained release (SR) to diminish systolic blood pressure. Material and methods: This was an experimental, open-label, longitudinal, descriptive, prospective, non-comparative, noncontrolled, non-randomized, clinical research study. 35 patients over 60 years old diagnosed with isolated systolic hypertension were included in the study. Metabolic parameters such as seric glucose, microalbuminuria, total cholesterol and triglycerides were also quantified. Results: Indapamide SR was shown to be effective in diminishing levels of systolic blood pressure by 10 mmHg or more with regards to baseline, as the study began with an average level of 179.58± 13.98 mmHg and, after 12 months of treatment with indapamide SR, reached an average of 133.80 ± 10.43 mmHg, a statistically significant reduction (p<0.05). Indapamide SR also produced reductions in levels of diastolic blood pressure from an initial average 81.66 ± 8.68 mmHg to 75.47 ± 8.02 mmHg after the 12 months of treatment (p<0.05).